YaxAB nanopore discriminates protein-drug complexes with 2.5 Da mass difference at near-atomic resolution
Background
High-resolution single-molecule sensing of biomolecular interactions, particularly protein-ligand interactions, is critical for understanding biological functions and developing therapeutics. Current methods often struggle with the sensitivity required to detect subtle differences in binding events, limiting their utility in early-stage drug discovery and diagnostics. The ability to precisely characterize these interactions at a near-atomic level could revolutionize how potential drug candidates are identified and validated, addressing a significant gap in current analytical technologies.
Study Design
Researchers developed a novel YaxAB nanopore system, modulating its electrostatic potential with LiCl, to detect molecular interactions. They used the BRD4 protein as a model, studying its interactions with histone peptides and various small-molecule drugs. The methodology involved electrical recordings to monitor current transitions and molecular dynamics simulations to confirm the oscillating dynamics of BRD4 within the nanopore. The primary endpoint was the nanopore's ability to discriminate between different protein-ligand complexes based on subtle mass differences.
Results
The YaxAB nanopore system successfully enabled the detection of molecular interactions at the single-molecule level. Electrical recordings and molecular dynamics simulations confirmed that the oscillating dynamics of BRD4 within the funneled nanopore generated distinct two-level current transitions between narrow- and wide-pore regions. Using parameters derived from these dual-level dynamics and their signal decomposition, the YaxAB nanopore sensing approach achieved sensitive discrimination of BRD4-small-molecule drug complexes. This system demonstrated an impressive capability to differentiate complexes with a subtle mass difference as small as 2.5 Da. This represents a near-atomic, high-resolution sensing capability.
The YaxAB nanopore system discriminated BRD4-small-molecule drug complexes with a mass difference as small as 2.5 Da, demonstrating near-atomic resolution.
Key Findings
- YaxAB nanopore with LiCl modulation detects protein-ligand interactions at single-molecule level.
- Oscillating BRD4 dynamics within the nanopore generate distinct two-level current transitions.
- Nanopore sensing discriminates BRD4-small-molecule drug complexes with high sensitivity.
- Achieved near-atomic resolution, detecting mass differences as small as 2.5 Da.
- Method holds promise for single-molecule drug discovery, proteomics, and diagnostics.
Why It Matters
This breakthrough in nanopore technology offers a powerful new tool for single-molecule-based drug discovery, potentially accelerating the identification and characterization of lead compounds. By enabling the sensitive discrimination of protein-drug complexes with near-atomic resolution, it could significantly enhance the precision of drug screening and target validation. For biohackers and researchers, this method could provide unprecedented insights into how small molecules interact with proteins, informing the design of more effective peptides or compounds. The technology's high-resolution capabilities also hold promise for advanced proteomics and diagnostics, allowing for the detection of subtle biomolecular changes relevant to disease states or therapeutic responses.
nanopore
single-molecule sensing
drug discovery
protein-ligand interaction
high-resolution
proteomics